Batavia Biosciences expands US and Dutch facilities to meet increasing demand

Batavia Biosciences is expanding its viral vector process development facilities in the US and its cleanroom facilities in the Netherlands to meet increasing market demand.

“Recent advances in cancer vaccines and gene therapy have given rise to a profound increase in the global demand for process development and clinical manufacturing of vector based products,” explained Chris Yallop, CSO Batavia Biosciences.

The expanded services to the US site in Medford, Massachusetts include complete pre-clinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development services for recombinant proteins and antibodies.

By expanding the cleanroom facilities in its Leiden site in the Netherlands, Batavia Biosciences will align its GMP capacity with increased R&D capability to further support the manufacturing of master cell banks and vaccine seed stocks.

“At Batavia Biosciences we are very much aware of the fact that the patient is waiting,” concluded Menzo Havenga, CEO Batavia Biosciences. “With the completion of this investment, the company is now better positioned to maintain the speed and quality of bringing candidate biopharmaceuticals from bench to clinic.”